These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36453110)

  • 1. Methotrexate, cytarabine, thiotepa and rituximab (MATRix) chemoimmunotherapy for primary central nervous system lymphoma: a Toronto experience.
    Suleman A; Liu J; Hicks LK; Drori AK; Crump M; Kridel R; Prica A; Berinstein N
    Haematologica; 2023 Apr; 108(4):1186-1189. PubMed ID: 36453110
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.
    Ferreri AJ; Cwynarski K; Pulczynski E; Ponzoni M; Deckert M; Politi LS; Torri V; Fox CP; Rosée PL; Schorb E; Ambrosetti A; Roth A; Hemmaway C; Ferrari A; Linton KM; Rudà R; Binder M; Pukrop T; Balzarotti M; Fabbri A; Johnson P; Gørløv JS; Hess G; Panse J; Pisani F; Tucci A; Stilgenbauer S; Hertenstein B; Keller U; Krause SW; Levis A; Schmoll HJ; Cavalli F; Finke J; Reni M; Zucca E; Illerhaus G;
    Lancet Haematol; 2016 May; 3(5):e217-27. PubMed ID: 27132696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma.
    Beca JM; Raza K; Mow E; Keech J; Kouroukis CT
    Leuk Lymphoma; 2020 May; 61(5):1097-1107. PubMed ID: 31931647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives].
    Nagane M
    Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
    Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
    J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress in primary CNS lymphoma.
    O'Brien PC; Seymour JF
    Lancet; 2009 Oct; 374(9700):1477-8. PubMed ID: 19767091
    [No Abstract]   [Full Text] [Related]  

  • 7. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
    Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
    Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-CHOP intensification with mid-cycle methotrexate and consolidating AraC/TT with BCNU/aHSCT in primary aggressive lymphoma with CNS involvement.
    Steinhardt MJ; Krummenast FC; Rosenwald A; Gerhard-Hartmann E; Heidemeier A; Einsele H; Topp MS; Duell J
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):205-214. PubMed ID: 34085097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
    Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
    Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
    Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
    Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
    Chen YB; Batchelor T; Li S; Hochberg E; Brezina M; Jones S; Del Rio C; Curtis M; Ballen KK; Barnes J; Chi AS; Dietrich J; Driscoll J; Gertsner ER; Hochberg F; LaCasce AS; McAfee SL; Spitzer TR; Nayak L; Armand P
    Cancer; 2015 Jan; 121(2):226-33. PubMed ID: 25204639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?
    de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J
    Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of high-dose etoposide cytarabine as consolidation following rituximab methotrexate temozolomide induction in newly diagnosed primary central nervous system lymphoma in immunocompetent patients.
    Birsen R; Willems L; Pallud J; Blanc E; Burroni B; Legoff M; Le Ray E; Pilorge S; Deau B; Franchi P; Vignon M; Kirova Y; Edjlali M; Houillier C; Soussain C; Varlet P; Dezamis E; Damotte D; Bouscary D; Tamburini J
    Haematologica; 2018 Jul; 103(7):e296-e299. PubMed ID: 29472354
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment Options for Recurrent Primary CNS Lymphoma.
    Kaulen LD; Baehring JM
    Curr Treat Options Oncol; 2022 Nov; 23(11):1548-1565. PubMed ID: 36205806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma.
    Yuan X; Xie Y; Xu N; Liu H; Chen P; Zhao A; Liang Y; Qian W
    Haematologica; 2024 Jun; 109(6):2005-2009. PubMed ID: 38356447
    [No Abstract]   [Full Text] [Related]  

  • 16. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
    Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
    Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose methotrexate and temozolomide associated with intrathecal liposomal cytarabine for the treatment of primary or secondary central nervous system lymphoma: a preliminary experience.
    Falchi L; Gunnellini M; Ferranti L; Liberati AM
    Clin Neurol Neurosurg; 2012 Dec; 114(10):1376-8. PubMed ID: 22516417
    [No Abstract]   [Full Text] [Related]  

  • 18. Primary leptomeningeal lymphoma masquerading as infectious tubercular meningitis.
    Sumangala S; Htwe T; Ansari Y; Martinez-Alvarez L
    BMJ Case Rep; 2021 Sep; 14(9):. PubMed ID: 34518180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose thiotepa-based conditioning regimens for relapsed lymphoma involving the central nervous system: from "orphan drug" to a standard-of-care?
    van der Weyden C; Prince HM
    Leuk Lymphoma; 2016; 57(1):1-3. PubMed ID: 26059059
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.
    Ferreri AJM
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):565-577. PubMed ID: 29222306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.